---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-005986"
form_type: "8-K"
ticker: "CLNN"
cik: "0001822791"
company_name: "Clene Inc."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T07:17:09.713925+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Clene reports positive long-term results from VISIONARY-MS LTE trial for CNM-Au8 in MS

## Summary
- Long-term CNM-Au8 treatment showed significant improvement in vision (LCLA) through 35 months, p<0.0001, mean +8.70 letters.
- Cognition improved via SDMT through 35 months, p<0.0001, mean +8.03 points.
- Global neurological function (mMSFC) improved through 35 months, p=0.018.
- No serious adverse events attributed to CNM-Au8; treatment well-tolerated with 94% compliance.
- Data presented at ACTRIMS Forum 2024; 55 of 69 eligible participants continued in LTE.

## SEC filing metadata
- accession: 0001437749-24-005986
- form_type: 8-K
- ticker: CLNN
- cik: 0001822791
- company_name: Clene Inc.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822791/000143774924005986/0001437749-24-005986-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822791/000143774924005986/clnn20240228_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-005986
- JSON: https://secwatch.observer/filing/0001437749-24-005986.json
- Plain text: https://secwatch.observer/filing/0001437749-24-005986.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.